Please assess the completion status of the following clinical trial:

Trial Title: RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Key inclusion Criteria:~* Diagnosis of relapsing form of MS~* Have declared a desire/plan to discontinue treatment with Tecfidera due to tolerability issues and/or lack of efficacy~* Expanded Disability Status Scale (EDSS) score 0 to 5.0 inclusive~* Other protocol defined inclusion criteria could apply~Key exclusion Criteria:~* Pregnant or lactating~* Significant renal or hepatic impairment or other significant disease that would compromise adherence and completion of the trial~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Rebif® via Rebidose® auto-injector (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).